Alkermes said its "continues to make meaningful progress on the previously announced planned separation of the company’s oncology business." The separation "would allow Alkermes to maintain its focus on researching, developing and commercializing therapies for people living with complex neurological conditions and is expected to accelerate and enhance the profitability of the remaining neuroscience business," the company said in its earnings release. Alkermes continues to expect to complete the separation in the second half of 2023, subject to various customary conditions, including final approval from Alkermes’ board of directors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALKS:
- Alkermes arbitration award better than expected, says Mizuho
- Alkermes price target raised to $31 from $29 at JPMorgan
- Alkermes receives second interim award in Janssen arbitration
- Alkermes submits Form 10 to SEC for planned separation of oncology business
- Alkermes price target raised to $37 from $36 at Mizuho